Boardroom Alpha
10-K primary document
ALNY · Annual Report (Form 10-K) · Filed February 12, 2026

Alnylam Pharmaceuticals Inc10-K exhibit

alny2025q4exhibit211.htm
Document

EXHIBIT 21.1
SUBSIDIARIES OF THE REGISTRANT
 
NameOwnership PercentageJurisdiction of Organization
Alnylam U.S., Inc.
100%Delaware
Alnylam U.S. Holdings, Inc.
100%Delaware
Alnylam UK Holdings Ltd.
100%United Kingdom
Alnylam Securities Corporation
100%Massachusetts
Sirna Therapeutics, Inc.
100%Delaware
Alnylam Australia Pty Ltd.
100%Australia
Alnylam Austria GmbH
100%Austria
Alnylam Belgium SPRL/BVBA
100%Belgium
Alnylam Brasil Farmaceutica Ltda.
99%Brazil
Alnylam (Bermuda) Ltd.
100%Bermuda
Alnylam Canada ULC
100%Canada
Alnylam France SAS
100%France
Alnylam Europe AG
100%Germany
Alnylam Germany GmbH
100%Germany
Alnylam Italy Srl
100%Italy
Alnylam Japan KK
100%Japan
Alnylam Netherlands BV
100%Netherlands
Alnylam Pharmaceuticals Spain SL
100%Spain
Alnylam Sweden AB
100%Sweden
Alnylam Switzerland GmbH
100%Switzerland
Alnylam Taiwan Co. Ltd.
100%Taiwan
ALNYPT Unipessoal LDA
100%Portugal
Alnylam UK Ltd.
100%United Kingdom


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer